Trade

with

Oncolytics Biotech Inc
(NASDAQ: ONCY)
AdChoices
0.4800
-0.0138
-2.79%
After Hours :
-
-
-

Open

0.5116

Previous Close

0.4938

Volume (Avg)

149.78k (366.18k)

Day's Range

0.4702-0.5137

52Wk Range

0.4000-2.89

Market Cap.

42.02M

Dividend Rate ( Yield )

-

Beta

1.86

Shares Outstanding

87.54M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 0

    • Net Income

    • -20.91M

    • Market Cap.

    • 42.02M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.86

    • Forward P/E

    • -2.01

    • Price/Sales

    • -

    • Price/Book Value

    • 2.88

    • Price/Cash flow

    • -1.87

      • EBITDA

      • -21.11M

      • Return on Capital %

      • -74.55

      • Return on Equity %

      • -88.05

      • Return on Assets %

      • -74.55

      • Book Value/Share

      • 0.15

      • Shares Outstanding

      • 87.54M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/21/2014
      Outperform
        • 1 Year Price Target

        • 3.78

        • Credit Rating

        • -

        • Analysts

        • 5

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -0.20

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -

          • 17.04

          • Net Income

            Q/Q (last year)

          • -

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 0.00

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • -

            • 82.75

            • Pre-Tax Margin

            • -

            • 39.38

            • Net Profit Margin

            • -

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • -

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • -

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.76

              • Current Ratio

              • 5.34

              • 2.92

              • Quick Ratio

              • 5.17

              • 2.35

              • Interest Coverage

              • -

              • 38.02

              • Leverage Ratio

              • 1.22

              • 2.21

              • Book Value/Share

              • 0.17

              • 4.79

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -1.93

                • 217.39

                • P/E Ratio 5-Year High

                • -30.21

                • 634.30

                • P/E Ratio 5-Year Low

                • -1.74

                • 124.82

                • Price/Sales Ratio

                • -

                • 9.52

                • Price/Book Value

                • 2.68

                • 8.61

                • Price/Cash Flow Ratio

                • -1.87

                • 50.51

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -88.05

                    (-101.30)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • -74.55

                    (-81.30)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • -88.05

                    (-101.30)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • -

                  • 117.08k

                  • Inventory Turnover

                  • -

                  • 1.48

                  • Asset Turnover

                  • -

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -21.23M
                  Operating Margin
                  -
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -1.87
                  Ownership

                  Institutional Ownership

                  8.80%

                  Top 10 Institutions

                  7.99%

                  Mutual Fund Ownership

                  2.84%

                  Float

                  98.61%

                  5% / Insider Ownership

                  -

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Selectra J. Lamarck Biotech

                  •  

                    1,119,300

                  • 0.00

                  • 1.27

                  • Scotia Canadian Small Cap Fund

                  •  

                    347,200

                  • 0.00

                  • 0.40

                  • Russell Smaller Companies Pool

                  •  

                    293,400

                  • 0.00

                  • 0.34

                  • Canadian Equity Fund

                  •  

                    187,710

                  • -48.77

                  • 0.21

                  • North Growth Canadian Equity

                  •  

                    147,000

                  • 0.00

                  • 0.17

                  • SEI Canadian Small Co Equity

                  •  

                    131,040

                  • -48.79

                  • 0.15

                  • iShares S&P/TSX Small Cap

                  •  

                    121,740

                  • 10.49

                  • 0.14

                  • AGF Canadian Growth Equity Class

                  •  

                    99,748

                  • -75.83

                  • 0.12

                  • Atomo Sicav Prisma

                  •  

                    15,000

                  • 0.00

                  • 0.02

                  • IG AGF Canadian Diversified Growth Fund

                  •  

                    12,675

                  • -70.37

                  • 0.01

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • 1832 Asset Management L.P

                  •  

                    2,826,250

                  • 0.00%

                  • 3.22

                  • Russell Frank Co

                  •  

                    1,237,100

                  • +22.98%

                  • 1.41

                  • SELECTRA MANAGEMENT COMPANY S.A.

                  •  

                    1,119,300

                  • 0.00%

                  • 1.27

                  • Bank of Nova Scotia

                  •  

                    500,000

                  • 0.00%

                  • 0.57

                  • Scotia Asset Management

                  •  

                    347,200

                  • 0.00%

                  • 0.40

                  • Morgan Stanley & Co Inc

                  •  

                    209,765

                  • -5.99%

                  • 0.24

                  • Canada Pension Plan Investment Board

                  •  

                    200,105

                  • 0.00%

                  • 0.23

                  • AGF Investments

                  •  

                    196,749

                  • -1.40%

                  • 0.22

                  • Arnhold & S. Bleichroeder Advisers, LLC

                  •  

                    188,600

                  • -55.85%

                  • 0.22

                  • VSR Financial Services, Inc.

                  •  

                    185,930

                  • +3.97%

                  • 0.21

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Slow Growth

                  Style

                  Small Value

                  Oncolytics Biotech, Inc., was incorporated on April 2, 1998 under the Business Corporations Act (Alberta) as 779738 Alberta Ltd. The Company is a development stage biopharmaceutical company that focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The Company focused on the development of oncolytic viruses for use as cancer therapeutics. Its product, REOLYSIN®, a proprietary formulation of the human reovirus, is in late stage (Phase III) clinical testing in head and neck cancers.

                  Key People

                  Dr. Bradley G. Thompson,PhD

                  CEO/Chairman of the Board/President/Director

                  Dr. Matthew C. Coffey,PhD

                  Co-Founder/COO/Director

                  Kirk J. Look

                  CFO

                  Mary Ann Dillahunty

                  Vice President, Divisional

                  Mr. Ed Levy,PhD

                  Director

                  • Oncolytics Biotech Inc

                  • 210, 1167 Kensington Crescent NW

                  • Calgary, AB T2N 1X7

                  • CAN.Map

                  • Phone: +1 403 670-7377

                  • Fax: +1 403 283-0858

                  • oncolyticsbiotech.com

                  Incorporated

                  1998

                  Employees

                  25

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: